Cardiac Marker Testing Market to Grow with a CAGR of 8.12% through 2029
Rising adoption of minimally invasive techniques are expected
to drive the Global Cardiac Marker Testing Market growth in the forecast
period, 2025-2029
According to TechSci Research report, “Cardiac
Marker Testing Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2029”, the Global Cardiac Marker Testing
Market stood at USD 4.17 billion in 2023 and is anticipated to grow with a CAGR
of 8.12% in the forecast period, 2025-2029. Cardiovascular diseases are a
significant global health concern, responsible for a substantial portion of
morbidity and mortality worldwide. One of the most prominent market drivers is the
increasing prevalence of cardiovascular diseases. Conditions like heart
attacks, congestive heart failure, and arrhythmias are becoming more common,
especially in aging populations. These diseases are a leading cause of death
globally, and their high incidence fuels the demand for cardiac marker testing.
Healthcare providers and clinicians rely on these tests to identify cardiac
issues early, assess risk factors, and monitor patients with known heart
conditions. Technological innovations have significantly enhanced the accuracy,
sensitivity, and speed of cardiac marker testing. Traditional biomarkers like
troponin and creatine kinase-MB (CK-MB) have been complemented by
high-sensitivity cardiac biomarkers, which can detect minute concentrations of
biomarkers in the blood. This technological progress has revolutionized cardiac
marker testing, enabling more precise and early diagnosis. It has also improved
patient management, as clinicians can make informed decisions about treatment
and interventions more quickly. Additionally, advancements in point-of-care
testing have made it easier to perform these tests in various healthcare
settings, further expanding their accessibility and usability.
Ongoing research and development in the field of
cardiac marker testing are expanding the scope and capabilities of these
diagnostics. This includes the discovery and validation of novel cardiac
biomarkers that can provide more comprehensive information about heart health.
Researchers are working to identify markers associated with specific cardiac
conditions, allowing for more targeted testing and tailored treatment plans.
Moreover, advancements in molecular biology and genetics are enabling the
development of personalized medicine approaches, tailoring treatment to an
individual's unique genetic makeup.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Cardiac Marker Testing Market”
The Global Cardiac Marker Testing Market is segmented
into type, guidance technique, anatomy, product type, regional distribution, and company
Based
on the product type, reagents and kits emerged as the dominant segment in the
global market for global cardiac marker testing market in 2023. Based on the Product Type, Reagents and Kits emerged as
the dominant segment in the global market for Global Cardiac Marker Testing
Market in 2023. Many
reagents and kits for cardiac marker testing are designed for point-of-care
testing (POCT). This means they provide rapid results, which is essential for
timely diagnosis and decision-making in critical care scenarios. Rapid testing
is a significant advantage for healthcare providers, as it allows for swift
intervention and improved patient outcomes. Reagents and kits are manufactured
under stringent quality control processes, ensuring consistent and reliable
performance. Healthcare professionals can have confidence in the accuracy of
the results obtained from these products. Reagents and kits are widely
available from multiple suppliers and manufacturers. This accessibility ensures
that healthcare providers have a range of options to choose from, promoting
healthy market competition and innovation. Reagents and kits are
generally more cost-effective than instruments, which often require a
significant upfront investment. The cost savings associated with reagents and
kits are particularly appealing to healthcare facilities and institutions
looking to manage their budgets efficiently.
Based on the biomarker type, troponin I
and troponin T emerged as the dominant segment in the global market for global cardiac marker testing market in 2023. Troponin I and Troponin T can
detect even small concentrations of these cardiac-specific proteins in the
bloodstream. This high sensitivity allows for the early detection of cardiac
injury, often before symptoms become evident. Early detection is crucial for
timely diagnosis and intervention, resulting in improved patient outcomes. Troponin
I and Troponin T have undergone extensive clinical validation, supporting their
clinical utility and relevance in cardiac marker testing. The wealth of
clinical data and research on these biomarkers has further solidified their
position as the preferred choice among healthcare providers. These troponins
not only aid in the diagnosis of acute coronary syndromes but also provide
prognostic information about the likelihood of future cardiovascular events. Based on the Diseases, Myocardial Infarction
emerged as the dominant segment in the global market for Global Cardiac Marker
Testing Market in 2023. Myocardial infarction is a highly acute
and life-threatening condition. It occurs when there is a sudden interruption
of blood flow to a part of the heart muscle, leading to tissue damage or death.
Due to its severity, prompt diagnosis and intervention are critical. Cardiac
marker testing, particularly troponin assays, is essential for rapid and
accurate diagnosis, guiding immediate treatment decisions, and improving
patient outcomes. Myocardial infarction is a leading cause of death worldwide.
It affects a significant portion of the global population, with millions of
cases occurring annually. This high incidence and prevalence result in a
continuous demand for cardiac marker testing to diagnose and manage heart
attacks. Cardiac markers, such as troponins, are specifically designed for
diagnosing myocardial infarction. These markers provide high sensitivity and
specificity in detecting cardiac injury, making them the primary tools for
diagnosing heart attacks. Therefore, the prevalence of myocardial infarction
naturally drives the demand for cardiac marker testing.
North America emerged as the dominant
player in the global cardiac marker testing market in 2023, holding the largest
market share. North America has one of the highest prevalence of
cardiovascular diseases in the world. Conditions such as heart disease,
myocardial infarction, and congestive heart failure are prevalent in the
region. The substantial burden of these diseases necessitates extensive cardiac
marker testing for diagnosis, risk assessment, and monitoring, driving the
demand for cardiac markers in the market. North America is a hub for
medical research and technological innovation. The region consistently leads in
the development of cutting-edge diagnostic assays, including high-sensitivity
troponin assays and novel cardiac biomarkers. The presence of leading medical
research institutions, universities, and healthcare companies fosters
innovation and drives the introduction of advanced cardiac marker tests to the
market.
Major companies operating in Global Cardiac
Marker Testing Market are:
- F. Hoffmann-La Roche Ag
- Abbott Laboratories Inc.
- Siemens Healthineers AG
- Danaher Corporation
- Biomérieux SA
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- Perkinelmer, Inc.
- Tosoh Corporation
- Becton, Dickinson and Company (BD)
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The Global Cardiac
Marker Testing Market is poised for significant growth in the coming years. The
rising incidence of cardiovascular diseases, particularly in aging populations,
will continue to fuel the demand for cardiac marker testing as a critical tool
for early detection, diagnosis, and monitoring. Technological advancements,
including high-sensitivity cardiac biomarkers and point-of-care testing, are
enhancing the precision and accessibility of these tests, further driving
market expansion. The integration of artificial intelligence and machine
learning for data analysis promises to enhance the interpretation and predictive
capabilities of cardiac marker tests. Moreover, global collaborations,
standardized protocols, and increased healthcare awareness will contribute to
the market's growth by ensuring that cardiac marker testing becomes an integral
part of cardiovascular care worldwide.” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Cardiac Marker Testing Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By
Product Type (Reagents and Kits, Instruments), By Biomarker type (Troponin I
and T, Creatine kinase-MB(CK-MB), Brain Natriuretic peptide (Bnp Or Nt-Probnp),
Myoglobin, High-sensitivity C-reactive protein (hs-CRP), Other Cardiac
Biomarkers), By Diseases (Myocardial Infarction, Congestive Heart Failure,
Acute Coronary Syndrome, Atherosclerosis, Ischemia), By End-use (Hospitals
& Clinics, Ambulatory Surgical Centers, Others) Region and Competition”, has evaluated
the future growth potential of Global Cardiac Marker Testing Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Cardiac Marker Testing Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com